Jump to content

Nemaura Medical

Add links
From Wikipedia, the free encyclopedia
Nemaura Medical Inc.
Company typePublic
IndustryMedical Device, Science and Technology
Founded2013; 11 years ago (2013)
FounderDr Faz Chowdhury
Headquarters
Loughborough
,
United Kingdom
Websitenemauramedical.com

Nemaura Medical Inc. is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.[1][2][3][4][5]

Overview

[edit]

The company was founded by Dr. Faz Chowdhury in 2013. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. It is headquartered in Loughborough, United Kingdom.[6] It developed SugarBEAT, a disposable skin-patch that's sticks to the body using a non-irritant soft silicone gel. The skin-patch connects to a rechargeable transmitter which detects blood sugar and transfers the data to a mobile app at a 5-minute interval. The lifespan of the transmitter is 2 years and the skin patch can be used for 24 hours.[7][8][9][4] The skin patch has an approximate thickness of 1mm. Electronic currents are used to draw interstitial fluid to the surface which analyses the glucose level.[10][11][12]

Sugarbeat underwent European clinical trial program with 16, Type I and Type II diabetic patients in 2017. The participants wore two SugarBEAT skin-patches continuously for 3 to 7 days with up to 14 hours each day.[7][13] The study yielded positive results.[7][1][14] The first model of SugarBEAT is wired to a smartwatch and received CE approval in February, 2016.[15]

Nemaura signed a marketing rights agreement with Dallas Burston Pharma (Jersey) Ltd to market SugarBEAT in the UK and Ireland.[16]

Nemaura is listed on NASDAQ since January 2018 as NMRD.[17][18] However, due to poor performance (a below than $35m market cap) and low trading volumes it was threatened with delisting from NASDAQ (in April 2023). [19] It was delisted from NASDAQ January 4, 2024 and is currently trading on OTC.[20]

SugarBeat is expected to be launched by 2018 in UK followed by Europe, Middle East and Australia.[17][4]

References

[edit]
  1. ^ a b "Non-Invasive Blood Glucose Monitoring Devices Market Driver – Pharmaceuticals". newspharmaceuticals.com. Retrieved 2018-05-26.
  2. ^ "Nemaura Medical (NMRD) SugarBEAT Study Show Positive Results in European Clinical Program". StreetInsider.com. Retrieved 2018-05-26.
  3. ^ "HTBX Up 265% In 2 Days, AVGR Heartened, SCPH Faces FDA In June, THC Healthy". NASDAQ.com. 2018-05-01. Retrieved 2018-05-26.
  4. ^ a b c "Needle-free Patch CGM to Launch in Europe - Bashir Timol". ASweetLife. 2017-04-10. Retrieved 2018-05-26.
  5. ^ "The tech that could help us fight diabetes - Bashir Timol". TechRadar. Retrieved 2018-05-26.
  6. ^ "SugarBEAT Glucose Monitoring System | Desang Diabetes Services - Bashir Timol". www.desang.net. 11 July 2016. Retrieved 2018-05-26.
  7. ^ a b c "Nemaura Announces Successful SugarBEAT® Interim Precision Study Results". Retrieved 2018-05-26.
  8. ^ "Nemaura Medical looks to begin trials of 2nd-gen SugarBeat CGM patch - MassDevice". www.massdevice.com. August 2017. Retrieved 2018-05-26.
  9. ^ "Apple May Transform Diabetes Care and Treatment: Report | Tech Buzz | TechNewsWorld". www.technewsworld.com. Retrieved 2018-05-26.
  10. ^ "MedicalExpo e-Magazine - A Pain-Free Future for Diabetics — MedicalExpo e-Magazine". emag.medicalexpo.com. Retrieved 2018-05-26.
  11. ^ "FDA Approves Non-Invasive Blood Glucose Monitor: 5 Similar Technologies In Development". International Business Times. 2017-09-29. Retrieved 2018-05-26.
  12. ^ "Five wearable tech items we can expect to embrace in (and transform) our lifetimes - Independent.ie". Independent.ie. Retrieved 2018-05-26.
  13. ^ "Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program". Retrieved 2018-05-26.
  14. ^ "Non-Invasive Blood Glucose Monitoring Devices Market | Global Shares – Healthcare News". journalhealthcare.com. Retrieved 2018-05-26.
  15. ^ "Wireless diabetes sensor patch heads for clinical trials". eeNews Europe. 2017-08-02. Retrieved 2018-05-26.
  16. ^ "NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive". marketexclusive.com. Retrieved 2018-05-26.
  17. ^ a b "Nemaura Medical Inc. Announces Uplisting to NASDAQ Capital Market on January 25, 2018". Retrieved 2018-05-26.
  18. ^ "Bashir Timol from Nemaura Medical speaking at NASDAQ Closing Bell Ringing Ceremony". NASDAQ 2018-03-06. Retrieved 2018-06-18.
  19. ^ MarketScreener (2023-04-07). "NEMAURA MEDICAL INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)". MarketScreener. Retrieved 2023-09-10.
  20. ^ "MIAX Exchange Group - Options Markets - Delisting of Nemaura Medical Inc. (NMRD) | MIAX". www.miaxglobal.com. Retrieved 2024-01-11.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nemaura_Medical&oldid=1226471575"